Glenmark Expands US Market Presence
Glenmark Secures US FDA Approval for Generic Flonase Nasal Spray to Boost Portfolio
Key Points
Glenmark recently launched nine products in the U.S., and its U.S. business grew 19.8% year-on-year in Q1 FY27 (excluding out-licensing income).
Glenmark's domestic formulation secondary sales rose 18.1% year-over-year in Q1 FY27, showing stronger performance than the broader Indian market, which grew about 12.2%.
Glenmark reported strong quarterly results in Q1 FY27: net profit rose to Rs 483 crore, revenue from operations climbed 23% to Rs 4,018 crore, and EBITDA increased 38.6% to Rs 805 crore, with EBITDA margin improving to 20%.
Market reaction to the FDA nod included a roughly 1.4% rise in Glenmark’s stock on the NSE, with shares trading around Rs 2,278.60 at about 9:35 am.
FDA approval details: Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray, is a final approval that is bioequivalent and therapeutically equivalent to Flonase; Glenmark will distribute the product in the U.S. via Glenmark Pharmaceuticals Inc., USA, with indications limited to Glenmark’s approved label.
Glenmark Pharmaceuticals has won U.S. FDA approval for a generic version of Flonase Nasal Spray, opening doors to a market worth roughly $295 million annually TipRanks. The drug — Fluticasone Propionate Nasal Spray at 0.05 mg per spray — is bioequivalent and therapeutically equivalent to Haleon's brand-name product. Glenmark plans to distribute it through its U.S. subsidiary, Glenmark Pharmaceuticals Inc., USA.
The approval comes as Glenmark's U.S. business surges. The company grew its domestic sales 19.8% year-on-year in the first quarter of fiscal year 2027, excluding licensing deals Investment Guru India. The stock rose about 1.4% on the news, with shares trading around Rs 2,278.60 in early trading.
Glenmark's Respiratory Portfolio Keeps Expanding
This FDA nod is the latest win in Glenmark's push into U.S. respiratory drugs. The company launched nine products in the U.S. recently and is clearly prioritizing this market Whale's Book. Fluticasone nasal spray — used to treat allergy and cold symptoms — fits squarely into that strategy.
Glenmark's overall U.S. performance looks robust. In Q1 FY27, the company's U.S. business climbed 19.8% year-on-year, well above the broader Indian market growth of 12.2% Investment Guru India. This momentum shows the company is executing its global expansion plans.
Strong Quarterly Results Fuel Investor Confidence
Glenmark's Q1 FY27 numbers were impressive across the board. Net profit hit Rs 483 crore, revenue climbed 23% to Rs 4,018 crore, and EBITDA jumped 38.6% to Rs 805 crore HDFC Sky. The EBITDA margin improved to 20%, showing better operational efficiency.
Domestic formulation sales — a key metric for Indian pharmaceutical companies — rose 18.1% year-over-year Sahi. These results, combined with the FDA approval, suggest Glenmark is gaining traction in both its home market and the U.S.
Why This Generic Matters for the U.S. Market
Flonase is one of America's best-selling over-the-counter nasal sprays. With annual sales around $295 million, the market is large and competitive Sahi. A generic version can take market share by offering lower prices while delivering the same active ingredient at the same strength.
Glenmark's success will depend on two things: getting the product into drugstore shelves and pricing it right TipRanks. Distribution and competition from other generics will determine how much of this market the company can capture. Still, the approval reinforces Glenmark's leadership in respiratory drugs.
Sentiment
Mostly PositivePublishers
10
Articles
6
Reach
16
